Contrasting Lisata Therapeutics (LSTA) and Its Peers

Lisata Therapeutics (NASDAQ:LSTAGet Rating) is one of 19 public companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it weigh in compared to its peers? We will compare Lisata Therapeutics to related companies based on the strength of its valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Earnings & Valuation

This table compares Lisata Therapeutics and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Lisata Therapeutics N/A -$27.47 million -0.60
Lisata Therapeutics Competitors $2.97 billion $132.19 million 10.09

Lisata Therapeutics’ peers have higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Lisata Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lisata Therapeutics N/A -27.24% -26.08%
Lisata Therapeutics Competitors -2,488.08% -69.13% -24.63%

Institutional & Insider Ownership

15.6% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by institutional investors. 2.2% of Lisata Therapeutics shares are held by insiders. Comparatively, 23.9% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Lisata Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Lisata Therapeutics’ peers have a beta of 4.01, suggesting that their average share price is 301% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Lisata Therapeutics and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lisata Therapeutics 0 0 2 0 3.00
Lisata Therapeutics Competitors 31 246 367 29 2.59

Lisata Therapeutics currently has a consensus price target of $15.00, suggesting a potential upside of 305.41%. As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 84.23%. Given Lisata Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Lisata Therapeutics is more favorable than its peers.

Summary

Lisata Therapeutics peers beat Lisata Therapeutics on 8 of the 13 factors compared.

About Lisata Therapeutics

(Get Rating)

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.